A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-group Study to Evaluate the Efficacy and Safety of study drug as Adjunctive Therapy in Participants with Mild to Moderate Alzheimer’s Disease Dementia.

Can I join this study?

Yes, you may be able to join the research study if you:

Has mild to moderate AD dementia (ie, Stage 4 or Stage 5 AD) based on the Alzheimer’s Association Revised Criteria for Diagnosis and Staging of Alzheimer’s Disease.

Is an individual of any sex/gender, from 55 to 90 years of age inclusive, at the time of providing the informed consent as applicable.

The participant (or legally acceptable representative) has provided documented informed consent for the study.

Study Duration:

Study will require approximately 30 months from the time the first participant (or their legally acceptable representative) provides documented informed consent until the last participant’s last study-related contact.

More information:

Indago Research & Health Center, Inc.

Call: 305-825-6588

The GN01 study is a new clinical research study from Eli Lilly and Company. It will test if an investigational medicine (a medicine being studied) is safe and could reduce weight in people with obesity or overweight.